概括
迪索皮拉米德和普拉诺洛尔都降低了心肌收缩能力,而慢性迪索皮拉米德显示出更强的效果. 普拉诺洛尔独特地阻断了β受体,它们的综合负面无otropic效应不是附加的.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 迪索皮拉米德和普拉诺洛尔是已知有心血管作用的药物.
- 了解它们对左心室性能和β阻塞的单独和综合影响对于临床实践至关重要.
研究的目的:
- 为了评估左心室表现的变化和单独和同时使用迪索皮拉米德和普罗普兰诺洛的β阻塞.
- 为了比较单剂量与慢性治疗的负面内效应.
主要方法:
- 健康的男性志愿者接受了随机的迪索皮拉米德和醇的药物治疗方案.
- 通过心声学评估左心室功能 (射出分数,缩时间间隔).
- 通过运动心率的变化来评估β阻塞.
主要成果:
- 这两种药物都表现出负的内活动,导致喷射分数略有下降.
- 迪索皮拉米德和普拉诺洛尔的单剂量具有相似的负面无otropic 效应.
- 慢性迪索皮拉米德治疗表现出比慢性普罗普拉诺洛尔更大的负面无otropic 效应.
- 只有兰醇显示出β-上腺素受体阻断活性.
- 同时使用并没有导致附加或协同的负面无otropic 效应.
结论:
- 迪索皮拉米德和普拉诺洛尔在单次治疗剂量时具有相似的负面内效应.
- 慢性迪索皮拉米德治疗比慢性普罗普拉诺洛尔具有更明显的负面无otropic 效应.
- 普罗普拉诺洛尔是唯一一种表现出β-上腺受体阻塞的药物.
- 联合使用不会增强负面内作用.
相关概念视频
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...